Insulin Requirements During Severe COVID-19 Were Relatively Low in Japanese Patients With Type 2 Diabetes: Two Case Reports.

Publication date: Oct 01, 2023

The global coronavirus disease 2019 (COVID-19) pandemic has caused myriad adverse effects on the pathology of other diseases. Numerous studies on COVID-19 have reported that, in patients with type 2 diabetes mellitus (T2DM) who have contracted severe COVID-19, glucose metabolism is exacerbated by multiple factors, such as severe inflammation, beta-cell dysfunction caused by the SARS-CoV-2 infection itself, corticosteroid therapy, vasopressor administration, and enteral or parenteral nutrition. Very high doses of insulin are often required in the acute phase of such patients; however, the factors that affect insulin requirements and to what extent remain unclear. A 50-year-old Japanese woman and a 67-year-old Japanese man, both with T2DM and obesity, were admitted to our hospital with severe COVID-19. Both patients required mechanical ventilation and were treated with dexamethasone and tocilizumab, an interleukin-6 (IL-6) receptor monoclonal antibody. Subcutaneous insulin injections failed to control the patients’ hyperglycemia, requiring up to 1. 83 and 1. 81 units/kg/day of intravenous insulin, respectively. Insulin requirements were rapidly decreased with improvement of the respiratory condition, termination of dexamethasone, and discontinuation of tube feeding. Both patients were discharged with oral antidiabetic agents alone. We experienced two Japanese patients who achieved satisfactory glycemic control with a lower intravenous insulin dose than previous reports. Comparing the clinical factors with the previous literature, ethnic differences in insulin sensitivity and the administration of IL-6 receptor antibodies may have been related to the relatively low insulin requirements.

Concepts Keywords
Coronavirus covid-19
Diabetes ethnic differences
Japanese il-6 receptor antibody
Therapy insulin requirements
type 2 diabetes


Type Source Name
disease MESH COVID-19
disease MESH Type 2 Diabetes
pathway REACTOME Glucose metabolism
disease MESH inflammation
disease IDO cell
disease MESH obesity
drug DRUGBANK Dexamethasone
drug DRUGBANK Tocilizumab
disease MESH hyperglycemia
disease VO dose
disease MESH insulin sensitivity

Original Article

(Visited 1 times, 1 visits today)